NeuroSense’s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

[ad_1] Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and…

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

[ad_1] SINGAPORE, Dec. 5, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based…

Cylera Named Leader in Connected Medical Device Security Solutions Report

[ad_1] Healthcare IoT security leader ranked as a leading vendor with distinguished customer impact and technology excellence  LONDON, Dec. 5, 2023 /PRNewswire/ — Healthcare IoT asset intelligence and security leader,…

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

[ad_1] SHANGHAI, Dec. 4, 2023 /PRNewswire/ — On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company…

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

[ad_1] BENGALURU, India, Nov. 30, 2023 /PRNewswire/ — Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business…

Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

[ad_1] –Nefecon® is the first approved medicine with an IgAN indication in China— –The approval marks a new era of IgAN treatment for Chinese patients– SHANGHAI, Nov. 23, 2023 /PRNewswire/…

FILAMENT HEALTH SIGNS NON-BINDING TERM SHEET FOR CONVERTIBLE NOTE IN CONNECTION WITH PLANNED BUSINESS COMBINATION

[ad_1] VANCOUVER, BC, Nov. 23, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical–stage natural psychedelic drug development company, today announced that the…

Brainomix Targets US Expansion with the Launch of its Cutting-Edge Stroke AI Platform Following Series of FDA Clearances

[ad_1] Launched at the Society of Vascular and Interventional Neurology (SVIN) Conference in Miami, the Brainomix 360 platform is powered by best-in-class algorithms, delivering a unique technology for both specialist and…

Venus Medtech’s Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

[ad_1] The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China,…

OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.

[ad_1] BELLEVUE, Wash. and SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ — Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company (“BLAC”), and OSR Holdings…